High lipoprotein(a) levels predict severity of coronary artery disease in patients hospitalized for acute myocardial infarction. Data from the French RICO survey


      • This study presents data on CAD severity in patients with acute MI and high Lp(a).
      • Patients with high Lp(a) had poorer survival during hospitalization for acute MI.
      • Very high Lp(a) levels (> 100 mg/dL) are associated with a severe CAD burden.
      • A call to action is needed for Lp(a) screening in all patients with acute MI.


      Lipoprotein(a) (Lp(a)) is a well-recognized independent risk factor for atherosclerotic cardiovascular disease (ASCVD). However, limited data are available on the relationship between coronary artery disease (CAD) burden and Lp(a) levels in patients with acute myocardial infarction (MI).


      The objective of this study was to assess the severity of CAD according to Lp(a) levels from a French regional registry of acute MI.


      CAD burden was assessed in 1213 consecutive patients hospitalized for acute MI in 2019-2020 who underwent coronary angiography. Patients were compared according to their Lp(a) levels: <50 mg/dL (normal), ≥50 mg/dL and ≤100 mg/dL (high) and >100 mg/dL (very high).


      The prevalence of high and very high Lp(a) was 13% and 6%, respectively. Median age, and rates of diabetes and smoking were similar in all groups. Patients with high or very high Lp(a) were more often under statin therapy, their corrected LDL-cholesterol levels were lower and previous ASCVD rates higher. When compared with lower levels, patients with very high Lp(a) levels had more elevated SYNTAX scores and more frequent multivessel disease. By multivariate logistic regression analysis, the odd ratio for the estimate of multivessel disease was the highest for patients with Lp(a) >100 mg/dL. Moreover, there was a gradual increase in the number of in-hospital deaths across the three Lp(a) groups (p=0.028).


      In real-world patients hospitalized for acute MI in France, very high Lp(a) levels are independently associated with a severe CAD burden, supporting the need for systematic screening of Lp(a) in these patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Clinical Lipidology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Nordestgaard BG
        • Langsted A.
        Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.
        J Lipid Res. 2016; 57: 1953-1975
        • Tsimikas S
        A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies.
        J Am Coll Cardiol. 2017; 69: 692-711
        • Wilson DP
        • Jacobson TA
        • Jones PH
        • et al.
        Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association.
        J Clin Lipidol. 2019; 13: 374-392
        • Shah NP
        • Pajidipati NJ
        • McGarrah RW
        • et al.
        Lipoprotein (a): an update on a marker of residual risk and associated clinical manifestations.
        Am J Cardiol. 2020; 126: 94-102
        • Erqou S
        • Kaptoge S
        • Perry PL
        • et al.
        • Emerging Risk Factors Collaboration
        Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.
        JAMA. 2009; 302: 412-423
        • Willeit P
        • Ridker PM
        • Nestel PJ
        • et al.
        Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
        Lancet. 2018; 392: 1311-1320
        • Weiss MC
        • Berger JS
        • Gianos E
        • et al.
        Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention.
        J Clin Lipidol. 2017; 11: 1177-1180
        • Oo HP
        • Giovannucci J
        • O'Brien RC
        • Hare DL
        The prevalence of elevated lipoprotein(a) in patients presenting with coronary artery disease.
        Heart Lung Circ. 2020; 29: 1682-1687
        • Sumarjaya IDGD
        • Nadha IKB
        • Lestari AAW.
        High lipoprotein(a) levels as a predictor of major adverse cardiovascular events in hospitalized-acute myocardial infarction patients.
        Vasc Health Risk Manag. 2020; 16: 125-132
        • Niccoli G
        • Chin D
        • Scalone G
        • et al.
        Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease.
        Atherosclerosis. 2016; 246: 214-220
        • Shi Y-P
        • Cao Y-X
        • Jin J-L
        • et al.
        Lipoprotein(a) as a predictor for the presence and severity of premature coronary artery disease: a cross-sectional analysis of 2433 patients.
        Coron Artery Dis. 2021; 32: 78-83
        • Zeller M
        • Steg PG
        • Ravisy J
        • et al.
        RICO Survey Working Group. Relation between body mass index, waist circumference, and death after acute myocardial infarction.
        Circulation. 2008; 118: 482-490
        • Sianos G
        • Morel M-A
        • Kappetein AP
        • et al.
        The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease.
        EuroIntervention. 2005; 1: 19-227
        • Yeang C
        • Witztum JL
        • Tsimikas S
        'LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering.
        Curr Opin Lipidol. 2015; 26: 169-178
        • Nordestgaard BG
        • Chapman MJ
        • Ray K
        • et al.
        Lipoprotein(a) as a cardiovascular risk factor: current status; European atherosclerosis society consensus panel.
        Eur Heart J. 2010; 31: 2844-2853
        • Mach F
        • Baigent C
        • Catapano AL
        • et al.
        ESC Scientific Document Group, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
        Eur Heart J. 2020; 41: 111-188
        • Danchin N
        • Farnier M
        • Zeller M
        • et al.
        FAST-MI investigators. Long-term outcomes after acute myocardial infarction in patients with familial hypercholesterolemia: The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction program.
        J Clin Lipidol. 2020; 14: 352-360
        • Ellis KL
        • Pang J
        • Chieng D
        • et al.
        Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: between scylla and charybdis.
        Clin Cardiol. 2018; 41: 378-384
        • Burgess S
        • Ference BA
        • Staley JR
        • et al.
        European Prospective Investigation Into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) Consortium, Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis.
        JAMA Cardiol. 2018; 3: 619-627
        • Lamina C
        • Kronenberg F.
        Lp(a)-GWAS-Consortium, Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a Mendelian randomization analysis.
        JAMA Cardiol. 2019; 4: 575-579
        • O'Donoghue ML
        • Morrow DA
        • Tsimikas S
        • et al.
        Lipoprotein(a) for risk assessment in patients with established coronary artery disease.
        J Am Coll Cardiol. 2014; 63: 520-527
        • Konishi H
        • Miyauchi K
        • Kasai T
        • et al.
        Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention.
        Am J Cardiol. 2015; 115: 157-160
        • Wong ND
        • Zhao Y
        • Sung J
        • Browne A.
        Relation of first and total recurrent atherosclerotic cardiovascular disease events to increased lipoprotein(a) levels among statin treated adults with cardiovascular disease.
        Am J Cardiol. 2021; 145: 12-17
        • Schwartz GG
        • Ballantyne CM
        • Barter PJ
        • et al.
        Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-Outcomes randomized clinical trial.
        JAMA Cardiol. 2018; 3: 164-168
        • Zaman T
        • Agarwal S
        • Anabtawi AG
        • et al.
        Angiographic lesion severity and subsequent myocardial infarction.
        Am J Cardiol. 2012; 110: 167-172
        • Tian J
        • Dauerman H
        • Toma C
        • et al.
        Prevalence and characteristics of TCFA and degree of coronary artery stenosis: an OCT, IVUS, and angiographic study.
        J Am Coll Cardiol. 2014; 64: 672-680
        • Gazzaruso C
        • Bruno R
        • Pujia A
        • et al.
        Lipoprotein(a), apolipoprotein(a) polymorphism and coronary atherosclerosis severity in type 2 diabetic patients.
        Int J Cardiol. 2006; 108: 354-358
        • Boroumand MA
        • Rekabi V
        • Davoodi G
        • et al.
        Correlation between lipoprotein(a) serum concentration and severity of coronary artery stenosis in an Iranian population according to Gensini score.
        Clin Biochem. 2008; 41: 117-120
        • Kral BG
        • Kalyani RR
        • Yanek LR
        • et al.
        Relation of plasma lipoprotein(a) to subclinical coronary plaque volumes, three-vessel and left main coronary disease, and severe coronary stenoses in apparently healthy African-Americans with a family history of early-onset coronary artery disease.
        Am J Cardiol. 2016; 118: 656-661
        • Chieng D
        • Pang J
        • Ellis KL
        • et al.
        Elevated lipoprotein(a) and low-density lipoprotein cholesterol as predictors of the severity and complexity of angiographic lesions in patients with premature coronary artery disease.
        J Clin Lipidol. 2018; 12: 1019-1026
        • Li S
        • Wu N-Q
        • Zhu C-G
        • et al.
        Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease.
        Atherosclerosis. 2017; 260: 67-74
        • Head SJ
        • Farooq V
        • Serruys PW
        • Kappetein AP.
        The SYNTAX score and its clinical implications.
        Heart. 2014; 100: 169-177
        • Maeda S
        • Abe A
        • Seishima M
        • Makino K
        • Noma A
        • Kawade M
        Transient changes of serum lipoprotein(a) as an acute phase protein.
        Atherosclerosis. 1989; 78: 145-150
        • Theofilis P
        • Vordoni A
        • Koukoulaki M
        • Vlachopanos G
        • Kalaitzidis RG.
        Dyslipidemia in chronic kidney disease: contemporary concepts and future therapeutic perspectives.
        Am J Nephrol. 2021; 52: 693-701
        • Tsimikas S
        • Stroes ESG.
        The dedicated "Lp(a) clinic": A concept whose time has arrived?.
        Atherosclerosis. 2020; 300: 1-9
        • Reyes-Soffer G
        • Ginsberg HN
        • Berglund L
        • et al.
        American heart association council on arteriosclerosis, thrombosis and vascular biology; council on cardiovascular radiology and intervention; and council on peripheral vascular disease. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association.
        Arterioscler Thromb Vasc Biol. 2022; 42: e48-e60
        • Gaubatz JW
        • Heideman C
        • Gotto Jr, AM
        • Morrisett JD
        • Dahlen GH
        Human plasma lipoprotein [a].
        Structural properties. Biol Chem. 1983; 258: 4582-4589
        • Yeang C
        • Witztum JL
        • Tsimikas S.
        Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements.
        J Lipid Res. 2021; 62100053
        • Puymirat E
        • Simon T
        • Cayla G
        • et al.
        USIK, USIC 2000, and FAST-MI investigators. Acute myocardial infarction: changes in patient characteristics, management, and 6-month outcomes over a period of 20 years in the FAST-MI program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015.
        Circulation. 2017; 136: 1908-1919
        • Tsimikas S
        • Bergmark C
        • Beyer RW
        • et al.
        Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes.
        J Am Coll Cardiol. 2003; 41: 360-370
        • Pirro M
        • Bianconi V
        • Paciullo F
        • et al.
        Lipoprotein(a) and inflammation: a dangerous duet leading to endothelial loss of integrity.
        Pharmacol Res. 2017; 119: 178-187
        • Langsted A
        • Kamstrup PR
        • Nordestgaard BG.
        Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk.
        Atherosclerosis. 2014; 234: 95-101